Greater Precision of HER2-Expressing Breast Cancer Treatment with 3D Pathology: New JelloX Research Collaboration

---
Greater Precision of HER2-Expressing Breast Cancer Treatment with 3D Pathology: New JelloX Research Collaboration
Vote:
0 0
Previous XCMG Technician College: A Global Workshop Cultivating Elite Industry Talents
Next HTX Completes Fireblocks Off-Exchange Integration, Advancing Institutional Trading Security and Efficiency

Related News

JelloX Research Collaborations Further Demonstrate Promise of 3D Pathology

JelloX Aims to Improve Patient-Centered Care with AI-powered 3D Digital Pathology

Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology

2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis

Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer at SABCS 2022

Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer at SABCS 2022

menu
menu